ASX ANNOUNCEMENT

23 November 2026

Michelle Hickey moves to Chief Technical Operations Officer

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that Ms Michelle Hickey, who joined Clarity in May 2026 as Senior Vice President (SVP), TCT Commercial Operations, is now stepping into the newly created role of Chief Technical Operations Officer (CTOO), leading the Global Technical Operations Team.

Ms Hickey is a seasoned technical operations executive, bringing three decades of diverse biopharmaceutical experience to Clarity. Her career spans work in multiple therapeutic areas, including radiopharmaceuticals, small molecules and biologics. She is passionate about maintaining focus on the patients by facilitating a culture of quality while advancing science and operational excellence. She brings expertise in chemistry, manufacturing and controls (CMC) strategy, early- and late-phase clinical drug development, manufacturing, validation, commercial operations, supply chain and program management. Ms Hickey has previously held senior leadership roles at such companies as Telix Pharmaceuticals and Clovis Oncology, where she was instrumental in the commercialisation of Rubraca®, Illuccix® and Gozellix®. Her foundational experience also includes key operational and quality positions at industry leaders such as Amgen and Wyeth Biopharma (Pfizer).

Ms Hickey holds a B.S. in Biotechnology from Rochester Institute of Technology and a mini-MBA in Biopharma Innovation from Rutgers Business School.

Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, commented, "In the role of CTOO, Michelle will further support the accelerating pace of development of Clarity's lead product, SAR-bisPSMA, given the recent closing of recruitment in the CLARIFY trial and completion of patient follow-up in the AMPLIFY study, along with the granting of the Breakthrough Therapy designation by the United States (US) Food and Drug Administration (FDA) that is expected to expedite the development of our next-generation product in biochemically recurrent prostate cancer. With topline data from both pivotal trials due in the first half of calendar year (CY) 2027 followed by a New Drug Application (NDA) submission, we are aligning our organisation to these important milestones to ensure a swift and successful launch.

"Michelle's strong and recent background in Global Commercial Operations and the required scale-up align with Clarity's growing focus on operations in the US. Since joining our Company, Michelle has quickly established herself as a senior member of the team, solidifying our technical operation plans. We look forward to working with Michelle and our team on meeting our FDA requirements with the receipt of our Breakthrough Therapy designation and preparing to meet the future market demand for our product as we inch ever closer to commericialisation in the largest oncology market in the world, the US.

"The Australian biotech industry has been under incredible pressure over the last two years, with a string of failed clinical results, starting with Opthea in March 2025 through to Actinogen Medical just last week. We are saddened by these events in Australian life sciences, particularly with the lack of Phase III success stories from Australian companies. But we take very seriously the role Clarity is playing in our local market as one of the very few 100% homegrown life sciences companies built from the benchtop of Australian science. As we head towards our very own Phase III trial readouts, we have been fortunate to build our positive SAR-bisPSMA product data to date, always head-to-head with current standard-of-care prostate-specific membrane antigen (PSMA) imaging, just recently becoming the only Company to translate science from Australia and receive Breakthrough Therapy designation. We have done all of our own development from pre-clinical to Phase III clinical trials, establishing Clarity as not only an Australian, but also a global biotech leader in radiopharmaceuticals to build a product from the lab. Our people are the Company's main asset in achieving our important mission of improving treatment outcomes for people with cancer, and the progress towards this ambition we have made to date is testament to Clarity's dedicated team. We

continue our commitment to our people, supporting our team, promoting diversity and providing unique opportunities for growth across the full spectrum of pharmaceutical development, from discovery and pre-clinical research through to clinical development and commercialisation of assets in blockbuster fields with the potential to deliver meaningful benefits for patients."

Disclaimer

^{64}Cu-SAR-bisPSMA is an unregistered product. Its safety and efficacy have not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that this product will become commercially available.

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers.

www.claritypharmaceuticals.com

For more information, please contact:

Clarity Pharmaceuticals

Dr Alan Taylor
Executive Chairperson
ataylor@claritypharm.com

Lisa Sadetskaya
Director, Corporate Communications
lisa@claritypharm.com

This announcement has been authorised for release by the Executive Chairperson.